Conventional Versus Hypofractionated Radiation in High Risk Prostate Patients — CHIRP

High-risk Prostate Cancer Clinical Trial

Official title:
A Phase II Randomized Control Trial of Conventional Versus Hypofractionated Radiation Regimen in Single Phase Using IMRT Technique and Long Term Androgen Suppression Therapy in High-risk Prostate Cancer Patients.

Status Recruiting

Clinical Trial Summary

Hypofractionated regimen in high-risk prostate cancer will allow the investigators to deliver higher biological doses to targets in order to improve tumor control and with acceptable rectal toxicity compared to conventional fractionation.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01488968
Study type	Interventional
Source	AHS Cancer Control Alberta
Contact	Albert Murtha
Phone	780-432-8518
Email	albert.murtha@ahs.ca
Status	Recruiting
Phase	N/A
Start date	March 2012
Completion date	December 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03362359` - Ga-68-PSMA-11 in High-risk Prostate Cancer	Phase 1/Phase 2
Recruiting	`NCT05558735` - Contribution of Canine Detection in the Diagnostic Strategy of High-risk Prostate Cancer (Prostate-K9-Detect)
Active, not recruiting	`NCT05223582` - Fluzoparib and Abiraterone in the preSurgery Treatment of Prostate Cancer: FAST Trial	Phase 2
Not yet recruiting	`NCT05593497` - A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss	Phase 2
Recruiting	`NCT03541928` - Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery	Phase 2